Saniona Beheer

Beheer criteriumcontroles 3/4

De CEO Saniona is Thomas Feldthus, benoemd in Apr2022, heeft een ambtstermijn van 2.58 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 3.98M, bestaande uit 60.7% salaris en 39.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.25% van de aandelen van het bedrijf, ter waarde SEK 4.07M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 8 jaar.

Belangrijke informatie

Thomas Feldthus

Algemeen directeur

SEK 4.0m

Totale compensatie

Percentage CEO-salaris	60.7%
Dienstverband CEO	2.6yrs
Eigendom CEO	1.3%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Thomas Feldthus's beloning veranderd ten opzichte van Saniona's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-SEK 82m
Mar 31 2024	n/a	n/a	-SEK 83m
Dec 31 2023	n/a	n/a	-SEK 96m
Sep 30 2023	n/a	n/a	-SEK 108m
Jun 30 2023	n/a	n/a	-SEK 33m
Mar 31 2023	n/a	n/a	-SEK 100m
Dec 31 2022	SEK 3m	SEK 1m	-SEK 212m
Sep 30 2022	n/a	n/a	-SEK 334m
Jun 30 2022	n/a	n/a	-SEK 445m
Mar 31 2022	n/a	n/a	-SEK 461m
Dec 31 2021	n/a	n/a	-SEK 411m
Sep 30 2021	n/a	n/a	-SEK 326m
Jun 30 2021	n/a	n/a	-SEK 280m
Mar 31 2021	n/a	n/a	-SEK 200m
Dec 31 2020	n/a	n/a	-SEK 73m
Sep 30 2020	n/a	n/a	-SEK 25m
Jun 30 2020	n/a	n/a	-SEK 5m
Mar 31 2020	n/a	n/a	-SEK 751k
Dec 31 2019	SEK 2m	SEK 2m	-SEK 69m
Sep 30 2019	n/a	n/a	-SEK 96m
Jun 30 2019	n/a	n/a	-SEK 53m
Mar 31 2019	n/a	n/a	-SEK 52m
Dec 31 2018	SEK 2m	SEK 2m	-SEK 41m
Sep 30 2018	n/a	n/a	-SEK 32m
Jun 30 2018	n/a	n/a	-SEK 61m
Mar 31 2018	n/a	n/a	-SEK 56m
Dec 31 2017	SEK 2m	SEK 2m	-SEK 49m

Compensatie versus markt: De totale vergoeding ($USD 359.70K ) Thomas } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 354.03K ).

Compensatie versus inkomsten: De vergoeding van Thomas is gestegen terwijl het bedrijf verliesgevend is.

CEO

Thomas Feldthus (64 yo)

2.6yrs

Tenure

SEK 3,981,000

Compensatie

Mr. Thomas Feldthus, M.Sc., MBA, served as Independent Director at Scandion Oncology A/S since 2018 until May 25, 2022. He serves as Chief Executive Officer at Saniona AB (publ) since April 30, 2022. He co...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jorgen Drejer	Founder	10.8yrs	SEK 412.00k	2.29% SEK 7.5m
Thomas Feldthus	Co-Founder & CEO	2.6yrs	SEK 3.98m	1.25% SEK 4.1m
Anita Milland	Chief Financial Officer	2.6yrs	geen gegevens	0.030% SEK 97.3k
Karin Nielsen	Chief Scientific Officer	8.7yrs	geen gegevens	0.19% SEK 613.3k
Palle Christophersen	Executive Vice President of Research	2.8yrs	SEK 1.38m	0.70% SEK 2.3m
Janus Larsen	Chief Development Officer	2.8yrs	geen gegevens	0.26% SEK 834.7k

2.8yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0RQJ wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jorgen Drejer	Founder	10.8yrs	SEK 412.00k	2.29% SEK 7.5m
Carl Sundberg	Independent Director	9.2yrs	SEK 430.00k	0.13% SEK 426.7k
Anna Ljung	Independent Director	6.8yrs	SEK 496.00k	0.0086% SEK 27.8k
Pierandrea Muglia	Independent Director	1.5yrs	SEK 117.00k	0.18% SEK 600.4k

8.0yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0RQJ wordt beschouwd als ervaren (gemiddelde ambtstermijn 8 jaar).

Saniona Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Insufficient new directors

Insufficient new directors

Saniona AB (publ), Annual General Meeting, May 29, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Saniona Initiates SAN711 Biomarker Study

Saniona Receives Regulatory Approval for San711 Biomarker Study

New major risk - Financial position

Second quarter 2024 earnings released: kr0.18 loss per share (vs kr0.34 loss in 2Q 2023)

First quarter 2024 earnings released: kr0.08 loss per share (vs kr0.35 loss in 1Q 2023)

Insufficient new directors

Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022)

Insufficient new directors

Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024

Saniona Announces the Selection of Its Proprietary GABAA A5 Negative Allosteric Modulator (NAM) Lead Compound, San2465

Saniona AB (publ) Strengthens Epilepsy Pipeline with Selection of SAN2355 as Clinical Candidate

Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022)

Saniona AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

Saniona AB (publ), Annual General Meeting, May 29, 2024

Saniona Promotes Kv7 Epilepsy Compound to Candidate Selection Phase

New major risk - Share price stability

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr1.42 loss in 2Q 2022)

New minor risk - Shareholder dilution

First quarter 2023 earnings released: kr0.35 loss per share (vs kr2.14 loss in 1Q 2022)

Insufficient new directors

Insufficient new directors

Insufficient new directors

Saniona AB Appoints Nomination Committee for the Annual General Meeting 2023

Insufficient new directors

Saniona AB (publ) to Report Q1, 2023 Results on May 25, 2023

Saniona AB (publ) Announces Anti-Inflammatory and Anti-Fibrotic Candidate SAN903 Is Ready for Clinical Studies

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: kr1.42 loss per share (vs kr1.67 loss in 2Q 2021)

Saniona Progresses Its Kv7 Epilepsy Program into Lead Optimization

Insufficient new directors

Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial

Insufficient new directors

Saniona’S Preclinical Candidate San903 Shows Robust Dampening of Fibrosis in Chronic Kidney Disease Model

Saniona Provides Update on Ongoing Review of Tesofensine in Mexico

Saniona Appoints Anita Milland as Chief Financial Officer, Effective April 30, 2022

Saniona Announces Voluntary Pause of Phase 2B Clinical Trials of Tesomet for Hypothalamic Obesity and Prader-Willi Syndrome

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Saniona AB (publ) to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial

Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome

Independent Director recently bought kr100k worth of stock

Third quarter 2021 earnings released: kr1.50 loss per share (vs kr1.24 loss in 3Q 2020)

Saniona Initiates Phase 1 Clinical Trial of SAN711

Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology

First quarter 2021 earnings released: kr1.34 loss per share (vs kr1.47 profit in 1Q 2020)

Full year 2020 earnings released: kr1.79 loss per share (vs kr2.95 loss in FY 2019)

Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity

Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd